Cibus targets initial Rice trait launches in LATAM in 2028 and U.S. in 2029
Company expects additional scale-up orders for biofragrances in H2 2026
Cibus projects annual net cash usage run-rate of about $35 mln exiting 2026
Overview
US agri-biotech firm's Q2 revenue rose yr/yr but missed analyst expectations
Net loss per share narrowed to $0.29 from $0.61 a year ago on cost cuts
Quarterly net cash usage fell 19% sequentially and 31% yr/yr
Result drivers
Cost reduction initiatives - Co said lower R&D and SG&A expenses were primarily due to cost-saving measures
Sustainable ingredients program - Co said revenue generation continued from commercial ramp-up with consumer-products partner
Rice commercialization - Co said it advanced Rice herbicide tolerance traits and expanded the contemplated Interoc relationship from two traits to five
Analyst coverage and valuation
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
CBUS•
